Until recently, Calithera Biosciences was a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. On January 9, 2023, we announced, after extensive consideration of potential strategic alternatives, that our Board of Directors had unanimously approved the dissolution and liquidation of Calithera pursuant to a plan of complete liquidation and dissolution, or the Plan of Dissolution, subject to stockholder approval. In connection with the Plan of Dissolution, we began discontinuing all clinical programs and commenced reducing our workforce, which includes the planned termination of most employees by the end of the first quarter, and began the wind-up of our operations.
In May 2023, we announced that the Company intends to hold a special meeting of stockholders on or about June 29, 2023 (the “Special Meeting”), for the purpose of approving the Company’s Plan of Dissolution. Additional information can be found in our press release dated May 19, 2023.
In June 2023, we began mailing the full set of the Special Meeting proxy materials, including the proxy statement and the proxy card, to our stockholders of record as of the close of business on May 25, 2023, a copy of which is available to view and download using the link below.
In June 2023, we announced that the Company was unable to achieve a quorum of stockholders at its Special Meeting scheduled to be held on June 29, 2023, and the Special Meeting was cancelled. Additional information can be found in our press release dated June 29, 2023.